Merck + Co., Inc.

Johns Hopkins University

Merck Sharp + Dohme Corp.

Merck Frosst Canada, Inc.

Nancy A Thornberry

Donald W Nicholson

William K Hagmann

Malcolm Maccoss

Kevin Tyler Chapman

Michel Gallant

Marc Labelle

Richard A Mumford

Jing Li

John R Thompson

Yves Gareau

Yun-Ping Zhou

Livia Angela Casciola-Rosen

John P Vaillancourt

Rejean Ruel

Felipe A Andrade

Dita M Rasper

Erin P Peterson

Kimberly M Fazil

Anthony Rosen

Jennifer Rotonda

Joseph W Becker

Weizhen Wu

Sophie Roy

Jin Shang

Jeffrey R Weidner

The present application features the use of the somatostatin subtype 3 receptor (SST3) as a target for affecting insulin secretion and for diagnosing diabetes related disorders. Glucose stimulated insulin secretion was found to be stimulated by knocking down expression of SST3 and through the use of a SST3 selective antagonist.

Diagnosis and treatment of type 2 diabetes and other disorders

The present invention provides a method of producing autoantigens, compositions comprising autoantigenic fragments and methods of using autoantigenic fragments in the treatment of a condition associated with an autoimmune response. Also provided are assays for the detection or assessment of an autoimmune response.

Autoantigenic fragments, methods and assays

Disclosed are novel chromophore containing compounds of Formula I and their use in determining interleukin-1&bgr; convertase (ICE) activity. ICE has been implicated in inflammatory or immune-based diseases of the lung and airways; central nervous system and surrounding membranes; the eyes and ears; joints, bones, and connective tissues; cardiovascular system including the pericardium; the gastrointestinal and urogenital systems; the skin and mucosal membranes.

Chromophore containing compounds and their use in determining interleukin-1&bgr; convertase activity

The apopain:Ac-DEVD-CHO complex has been crystallized and its structure determined by x-ray crystallography. Based upon this crystal structure of the complex, a method for identifying inhibitors of apopain is presented which comprises designing putative inhibitors having specific contacts with apopain, making the putative inhibitors, and testing the putative inhibitors for their ability to inhibit apopain.

Method for identifying inhibitors for apopain based upon the crystal

Growing community of inventors

Westfield, NJ, United States of America

Nancy A Thornberry